Johnson & Johnson

Applications for the @TIME Healthcare Champion of the Year, in partnership with J&J, a branded award, close August 28, 2026.

Every day, healthcare professionals go above and beyond to improve the lives of patients, strengthen communities and advance the future of care. Now is the time to recognize their impact.

Know a healthcare champion making a difference? Nominate them before the deadline: social.jnj.com/4hv2qoG

A paid partnership with TIME.

#NEWS: The U.S. FDA has authorized the OTTAVA™ Robotic Surgical System—the world's first table-integrated soft tissue robotic system.

This U.S. milestone reflects years of collaboration with surgeons, engineers and clinical teams to rethink how robotic surgery can better serve clinicians, hospitals and patients.

Built to open new possibilities in surgery, OTTAVA is designed with robotic arms integrated directly into the surgical table, a significantly smaller footprint, automated features and connection to an open digital ecosystem designed to turn surgical data into meaningful insights over time.

Learn more: social.jnj.com/4bPSceP

*Intended for U.S. audiences

Great care takes more than skill—it takes dedication, creativity and drive.

Nominations are still open for the @TIME Healthcare Champion of the Year, in partnership with J&J, a branded award we're proud to help bring to life.

It looks beyond titles to recognize the people shaping the future of health. Whether they work in hospitals, clinics or community-based programs, professionals at every career stage are eligible.

Know someone driving change in healthcare? Nominate them by August 28: social.jnj.com/44HiGvj

A paid partnership with TIME.

Healthcare professionals shape the future of care every day through innovation, resilience and a deep commitment to the people they serve.

That's why we at J&J are excited to partner with @TIME to launch the Healthcare Champion of the Year, a branded award recognizing a leader whose work is driving meaningful change across the health system.

As the demands of healthcare workers continue to rise, this award spotlights what's possible when individuals are empowered to lead where it matters most.

Is this you, or do you know someone like this? Submit your nomination by August 28: social.jnj.com/4w1HwSw

A paid partnership with TIME.

Join our Q2 2026 #earnings call and webcast now: social.jnj.com/4bDB0ZW $JNJ

We’re committed to helping improve sight for more than 40 million patients in the U.S. and around the world.

This week, we announced a more than $1 billion investment in Jacksonville, Florida to strengthen our Vision operations.

As part of our $55 billion U.S. investment in manufacturing, technology and R&D, this commitment includes a new distribution facility, and advanced manufacturing and packaging technologies, to expand capacity and enhance supply chain resilience.

Learn more: social.jnj.com/4glVsSn

Join our Q1 2026 #earnings call and webcast now: social.jnj.com/4c5hSVw $JNJ

#NEWS: The U.S. FDA has approved our new treatment for patients 12 and older with moderate to severe plaque psoriasis, bringing a fundamentally different systemic treatment option to patients and physicians.

Learn more: social.jnj.com/3NlAPK5

For U.S. Audience Only

#NEWS: The U.S. FDA has approved a breakthrough extended depth of focus (EDOF) intraocular lens intended for use in cataract surgery.

This advanced technology is designed to deliver clarity of vision with reduced visual symptoms, helping patients see the world as they expect¹. Learn more: ​social.jnj.com/3NosQf4

For U.S. Audiences Only.

¹TECNIS PureSee™ IOL with TECNIS SIMPLICITY™ Delivery System, Model DEN00V. Directions for Use, current revision.

Join our Q4 and full-year 2025 #earnings call and webcast now: social.jnj.com/4roFOrV $JNJ

#NEWS The U.S. FDA has approved a new subcutaneously administered therapy for the treatment of EGFR-mutated advanced non–small cell lung cancer (NSCLC) in adults.

This treatment option brings us one step closer to delivering more personalized care centered on the patient experience.

Learn more: social.jnj.com/3YDIhly

#JNJOncology #LungCancer

Today, the U.S. FDA approved one of our therapies as an adjunctive treatment for adults living with major depressive disorder (MDD) – offering hope to the 2 in 3 patients who experience residual symptoms despite their antidepressant treatment. Learn more here: social.jnj.com/4965svt

What's the difference between AI hype and AI value in healthcare? At #HLTHUSA, our CIO Jim Swanson shared what successful teams focus on to deliver real results that advance health.

Driven by our commitment to closing the gap between communities and care, we're excited to announce that we're teaming up with the @nyjets to promote better health in the local community, which is home to both our world headquarters and the Jets.

Join us in honoring healthcare champions as we build a healthier community together: jnj.com/our-company/jo…

We’re gearing up for #HLTHUSA October 19-22. Don’t miss sessions on AI’s real-world impact, breaking barriers in cancer care and how nurses are fueling healthcare innovation: social.jnj.com/48P34cz

Join our Q3 2025 #earnings call and webcast now: social.jnj.com/3KM9uPz $JNJ

Today we’re announcing our intent to separate our Orthopaedics business. We’re confident this move would further strengthen the focus of Johnson & Johnson on our six key growth areas – Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. It would also establish a standalone Orthopaedics business, operating as Depuy Synthes, that would be the largest, most comprehensive orthopaedics-focused company with leading market share positions across major product categories.

Learn more: social.jnj.com/3KPCOob

Struggling to see clearly due to astigmatism and finding it hard to focus up close from presbyopia?

We're changing that with ACUVUE® OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM—the first and only daily disposable contact lens designed to treat both astigmatism and presbyopia.¹

Using advanced technology, these lenses provide crisp, clear vision at all distances and in all lighting conditions plus all day comfort so patients can enjoy all of life’s special moments.²

Learn more: social.jnj.com/4nxyPf4

Click for important safety information: jnjvisionpro.com/en-us/importan…

Join our Q1 2025 #earnings call and webcast now: social.jnj.com/4cuf3vO $JNJ

We’re expanding U.S. manufacturing, technology and research & development of innovative healthcare solutions to impact health for humanity: social.jnj.com/4kEIPlj